NCT06063876
Experimental Peri-implant Mucositis on Implant Sites That Were Previously Treated With or Without Implantoplasty
Enrolling by Invitation
NAAges 18–80InterventionalPreventionUniversity of PittsburghInvestigator-initiated
~30 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:Induction of experimental peri-implant mucositisResolution of experimental peri-implant mucositis
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in the modified Gingival Index (mGI) between 21 and 42 days
Measured over At 21 and 42 days
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Andrea Ravida · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Aged 18-80 years
In good general health, (at least ASA 2)
Previously treated implants must have probing depths (PD) ≤ 4 mm
Previously treated implants must have \<50% bone loss around the implant of interest (assessed radiographically)
Patients must have been treated previously for peri-implantitis with or without IP, with at least 1 thread or 2 mm of implant surface exposed in the oral cavity.
Have little to no bacteria on the implant(s) of interest (modified Plaque Index of \<1) by Day 0
Have healthy gums that do not bleed around the implant(s) of choice (modified Gingival index \<1) by Day 0
Have evidence of stable bone levels around the treated implant for \> 6 months
Exclusion
Active infectious diseases of any kind.
Medical conditions which require premedication prior to dental treatments/visits.
Pregnant women or planning to become pregnant (self-reported).
Patients with congenital or metabolic bone disorders (ie. osteoporosis, vitamin D deficiency, parathyroid disease, etc.)
Current heavy smokers: Subjects who have smoked more than 1 pack/day within 6 months of study onset (self-reported)
Subjects with co-morbid conditions (i.e., uncontrolled diabetes, cardiovascular disease, impaired kidney function, heart murmur, rheumatic fever, bleeding disorder, hepatitis, tuberculosis, HIV) that would affect the study outcome or interpretation of study results will be excluded.
Concomitant medications: Subjects on significant concomitant drug therapy for systemic conditions (i.e., Chronic anti-inflammatory medication, antibiotics, anticoagulants, any medication initiated \<3 months prior to the screening visit) will not be included in the study. Occasional short-term use (7-14 days) of analgesics or common cold medication is permitted. Such use of these medications will be reviewed and recorded by the Investigator.
What this trial measures
- Changes in the modified Gingival Index (mGI) between 21 and 42 daysAt 21 and 42 days
The mGI will be assessed according to the following criteria: Score 0 - No bleeding on probing; Score 1 - Bleeding dot; Score 2 - Continuous line of blood that fills the sulcus; Score 3 - Profuse bleeding and/or hemorrhage drip. Changes in the scores between day 21 and day 42 will be determined, being 0 minimum and 3 maximum. The mGI will be assessed weekly.